BIRC5 and breast carcinoma: Moreover, the concomitant treatment of MDA-MB-231 breast cancer cells with statins and Dasatinib completely blocked the YAP/TAZ transcriptional activity, as observed by the dramatic drop in the expression of the well established YAP/TAZ target genes CTGF, CYR61, ANKRD1 and BIRC5 and the TEAD-responsive reporter 8XGTII (Figure 4D and 4E) [36, 40].